The second trial over Novartis’s heart failure treatment ‘Entresto (valsartan+ sacubitril) again ended with the victory of the Korean generic companies.

If the companies succeed in winning the remaining 2 suits, the companies will be one step closer to the early release of their generics.

Generic companies win first and second trials on Entresto’s composition and use patent

According to industry sources on the 10th, the Patent Court of Korea ruled against the plaintiff (Novartis) in the second patent invalidation trial that Novartis filed against 10 generic companies, including Hanmi Pharmaceutical, on the 9th.

The patent was a composition/use pate